# A Postmarketing Study of the Risk of Venous Thromboembolism (Blood Clots), Myocardial Infarction (Heart Attacks), and Stroke Among Women Using ORTHO EVRA (Norelgestromin and Ethinyl Estradiol Contraceptive Patch) Compared With Women Who Take Oral Contraceptives for Birth Control

> **NCT00377988** · — · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 423 (actual)

## Conditions studied

- Contraception
- Female Contraception

## Interventions

- **DRUG:** Transdermal Contraceptive System
- **DRUG:** Norgestimate-containing oral contraceptives with EE

## Key facts

- **NCT ID:** NCT00377988
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2002-04
- **Primary completion:** 2008-10
- **Final completion:** 2008-10
- **Target enrollment:** 423 (ACTUAL)
- **Last updated:** 2016-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00377988

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00377988, "A Postmarketing Study of the Risk of Venous Thromboembolism (Blood Clots), Myocardial Infarction (Heart Attacks), and Stroke Among Women Using ORTHO EVRA (Norelgestromin and Ethinyl Estradiol Contraceptive Patch) Compared With Women Who Take Oral Contraceptives for Birth Control". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00377988. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*